Literature DB >> 22028427

Apolipoproteins: metabolic role and clinical biochemistry applications.

Marek H Dominiczak1, Muriel J Caslake.   

Abstract

Lipoprotein metabolism is dependent on apolipoproteins, multifunctional proteins that serve as templates for the assembly of lipoprotein particles, maintain their structure and direct their metabolism through binding to membrane receptors and regulation of enzyme activity. The three principal functions of lipoproteins are contribution to interorgan fuel (triglyceride) distribution (by means of the fuel transport pathway), to the maintenance of the extracellular cholesterol pool (by means of the overflow pathway) and reverse cholesterol transport. The most important clinical application of apolipoprotein measurements in the plasma is in the assessment of cardiovascular risk. Concentrations of apolipoprotein B and apolipoprotein AI (and their ratio) seem to be better markers of cardiovascular risk than conventional markers such as total cholesterol and LDL-cholesterol. Apolipoprotein measurements are also better standardized than the conventional tests. We suggest that measurements of apolipoprotein AI and apolipoprotein B are included as a part of the specialist lipid profile. We also suggest that lipoprotein (a) should be measured as part of the initial assessment of dyslipidaemias because of its consistent association with cardiovascular risk. Genotyping of apolipoprotein E isoforms remains useful in the investigation of mixed dyslipidaemias. Lastly, the role of postprandial metabolism is increasingly recognized in the context of atherogenesis, obesity and diabetes. This requires better markers of chylomicrons, very-low-density lipoproteins and remnant particles. Measurements of apolipoprotein B48 and remnant lipoprotein cholesterol are currently the key tests in this emerging field.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22028427     DOI: 10.1258/acb.2011.011111

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  54 in total

Review 1.  Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors:  Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-06       Impact factor: 4.698

2.  Effect of oxidation on the structure of human low- and high-density lipoproteins.

Authors:  Cristiano L P Oliveira; Priscila R Santos; Andrea M Monteiro; Antonio M Figueiredo Neto
Journal:  Biophys J       Date:  2014-06-17       Impact factor: 4.033

3.  Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development.

Authors:  Arthur T Kopylov; Alexander A Stepanov; Kristina A Malsagova; Deepesh Soni; Nikolay E Kushlinsky; Dmitry V Enikeev; Natalia V Potoldykova; Andrey V Lisitsa; Anna L Kaysheva
Journal:  Molecules       Date:  2020-01-31       Impact factor: 4.411

Review 4.  Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration.

Authors:  Jeriel T R Keeney; Aaron M Swomley; Sarah Förster; Jessica L Harris; Rukhsana Sultana; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2013-01       Impact factor: 3.494

5.  A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins.

Authors:  Valentin Blanchard; Damien Garçon; Catherine Jaunet; Kevin Chemello; Stéphanie Billon-Crossouard; Audrey Aguesse; Aya Garfa; Gilles Famchon; Amada Torres; Cédric Le May; Matthieu Pichelin; Edith Bigot-Corbel; Gilles Lambert; Bertrand Cariou; Samy Hadjadj; Michel Krempf; Kalyane Bach-Ngohou; Mikaël Croyal
Journal:  J Lipid Res       Date:  2020-05-13       Impact factor: 5.922

6.  Proteomic investigations on the effect of different membrane materials on blood protein adsorption during haemodialysis.

Authors:  Andrea Urbani; Vittorio Sirolli; Santina Lupisella; Stefano Levi-Mortera; Barbara Pavone; Luisa Pieroni; Luigi Amoroso; Roberto Di Vito; Sonia Bucci; Sergio Bernardini; Paolo Sacchetta; Mario Bonomini
Journal:  Blood Transfus       Date:  2012-05       Impact factor: 3.443

7.  High serum apolipoprotein E determines hypertriglyceridemic dyslipidemias, coronary disease and apoA-I dysfunctionality.

Authors:  Altan Onat; Günay Can; Ender Ornek; Erkan Ayhan; Nihan Erginel-Ünaltuna; Sani N Murat
Journal:  Lipids       Date:  2012-10-25       Impact factor: 1.880

8.  Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study.

Authors:  Valentin Blanchard; Stéphane Ramin-Mangata; Stéphanie Billon-Crossouard; Audrey Aguesse; Manon Durand; Kevin Chemello; Brice Nativel; Laurent Flet; Maud Chétiveaux; David Jacobi; Jean-Marie Bard; Khadija Ouguerram; Gilles Lambert; Michel Krempf; Mikaël Croyal
Journal:  J Lipid Res       Date:  2018-03-14       Impact factor: 5.922

9.  A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes.

Authors:  Tamayo Kato; Yasuyuki Ushiogi; Hitoshi Yokoyama; Shigeo Hara; Akira Matsunaga; Eri Muso; Takao Saito
Journal:  CEN Case Rep       Date:  2019-01-30

10.  Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model.

Authors:  Hongchao Zheng; Ning Li; Yueyou Ding; Peizhi Miao
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.